产KPC-3型肺炎克雷伯菌分离株中头孢他啶-阿维巴坦耐药性的首次报告
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
作者信息
Humphries Romney M, Yang Shangxin, Hemarajata Peera, Ward Kevin W, Hindler Janet A, Miller Shelley A, Gregson Aric
机构信息
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
出版信息
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.
Abstract
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
摘要
头孢他啶-阿维巴坦是美国食品药品监督管理局（FDA）批准用于治疗耐碳青霉烯类肠杆菌科细菌的首个抗菌药物。阿维巴坦是一种非β-内酰胺类β-内酰胺酶抑制剂，可使包括肺炎克雷伯菌碳青霉烯酶（KPC）在内的A类丝氨酸碳青霉烯酶失活。我们报告了1株产KPC的肺炎克雷伯菌分离株，该菌株对头孢他啶-阿维巴坦耐药（MIC为32/4 μg/ml），分离自1例既往未接受过头孢他啶-阿维巴坦治疗的患者。
相似文献
1
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.产KPC-3型肺炎克雷伯菌分离株中头孢他啶-阿维巴坦耐药性的首次报告
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.
2
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
3
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.肺炎克雷伯菌碳青霉烯酶亚型、超广谱β-内酰胺酶及孔蛋白突变对头孢他啶-阿维巴坦体外抗碳青霉烯类耐药肺炎克雷伯菌活性的影响
Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7. doi: 10.1128/AAC.00548-15. Epub 2015 Jul 13.
4
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
5
Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the DY Substitution in the KPC-2 β-Lactamase.因KPC-2 β-内酰胺酶中的DY取代导致阿维巴坦抑制作用受损及对头孢他啶-阿维巴坦联合制剂耐药
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00451-17. Print 2017 Jul.
6
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
7
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.头孢他啶-阿维巴坦对一组碳青霉烯类耐药肠杆菌科挑战株的活性：OmpK36 L3 改变和具有头孢他啶水解活性的β-内酰胺酶导致 MIC 值升高。
Int J Antimicrob Agents. 2020 Jul;56(1):106011. doi: 10.1016/j.ijantimicag.2020.106011. Epub 2020 May 15.
8
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.鉴定头孢他啶-阿维巴坦和亚胺培南-雷利巴坦对碳青霉烯类耐药肠杆菌科的活性谱和治疗窗。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00642-17. Print 2017 Sep.
9
In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.2015-2016 年在希腊医院分离的产非 MBL 碳青霉烯酶肺炎克雷伯菌的亚胺培南-雷利巴坦体外活性。
Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1143-1150. doi: 10.1007/s10096-019-03517-y. Epub 2019 Mar 1.
10
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.在对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌中表达的KPC-31与相关检测问题有关。
J Antimicrob Chemother. 2019 Aug 1;74(8):2464-2466. doi: 10.1093/jac/dkz156.
引用本文的文献
1
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.头孢他啶-阿维巴坦用于重症患者：一项多中心观察性研究。
Antibiotics (Basel). 2025 Aug 5;14(8):797. doi: 10.3390/antibiotics14080797.
2
Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline.拷贝数灵活性促进了对不断增加的抗生素压力的异质性耐药，并威胁到β-内酰胺类药物研发进程。
Nat Commun. 2025 Jul 1;16(1):5721. doi: 10.1038/s41467-025-60828-9.
3
A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases.105位的甘氨酸会导致A类β-内酰胺酶对克拉维酸和阿维巴坦产生耐药性。
J Biol Chem. 2025 Jun 6;301(7):110347. doi: 10.1016/j.jbc.2025.110347.
4
Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in clinical isolates.头孢他啶-阿维巴坦与美罗培南交叉耐药性的多组学分析确定了临床分离株中的共同机制和菌株特异性机制。
mBio. 2025 Jul 9;16(7):e0389624. doi: 10.1128/mbio.03896-24. Epub 2025 Jun 4.
5
Rapid diagnostics to enhance therapy selection for the treatment of bacterial infections.用于改善细菌感染治疗中治疗方案选择的快速诊断方法。
Curr Pharmacol Rep. 2023 Aug;9(4):198-216. doi: 10.1007/s40495-023-00323-1. Epub 2023 Jun 29.
6
Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.头孢他啶-阿维巴坦的表型超快速抗菌药物敏感性试验：支持抗菌药物管理
Microorganisms. 2025 Feb 13;13(2):414. doi: 10.3390/microorganisms13020414.
7
High-level cefiderocol and ceftazidime/avibactam resistance in KPC-producing Klebsiella pneumoniae associated with mutations in KPC and the sensor histidine kinase EnvZ.产KPC的肺炎克雷伯菌中与KPC和传感组氨酸激酶EnvZ突变相关的对头孢地尔和头孢他啶/阿维巴坦的高水平耐药性
J Antimicrob Chemother. 2025 Apr 2;80(4):1155-1157. doi: 10.1093/jac/dkaf048.
8
Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing Klebsiella pneumoniae.产KPC肺炎克雷伯菌中质粒携带的柠檬酸铁转运系统赋予的头孢地尔耐药性
Emerg Infect Dis. 2025 Jan;31(1):123-124. doi: 10.3201/eid3101.241426.
9
Development and validation of a nomogram-based risk prediction model for carbapenem-resistant in hospitalized patients.住院患者耐碳青霉烯类药物基于列线图的风险预测模型的开发与验证
Microbiol Spectr. 2025 Jan 7;13(1):e0217024. doi: 10.1128/spectrum.02170-24. Epub 2024 Dec 6.
10
Amidine containing compounds: Antimicrobial activity and its potential in combating antimicrobial resistance.含脒化合物：抗菌活性及其在对抗抗菌药物耐药性方面的潜力。
Heliyon. 2024 May 31;10(15):e32010. doi: 10.1016/j.heliyon.2024.e32010. eCollection 2024 Aug 15.
本文引用的文献
1
Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.针对从美国医院分离出的肠杆菌科细菌（2011年至2013年）进行的头孢他啶-阿维巴坦活性测试以及产β-内酰胺酶菌株的特征分析。
Antimicrob Agents Chemother. 2015;59(6):3509-17. doi: 10.1128/AAC.00163-15. Epub 2015 Apr 6.
2
Avibactam and inhibitor-resistant SHV β-lactamases.阿维巴坦与耐抑制剂的SHVβ-内酰胺酶
Antimicrob Agents Chemother. 2015 Jul;59(7):3700-9. doi: 10.1128/AAC.04405-14. Epub 2015 Feb 17.
3
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.对阿维巴坦抑制作用具有抗性的β-内酰胺酶KPC-2变体。
Antimicrob Agents Chemother. 2015 Jul;59(7):3710-7. doi: 10.1128/AAC.04406-14. Epub 2015 Feb 9.
4
Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.治疗多重耐药革兰氏阴性菌时的意外挑战：铜绿假单胞菌存档菌株对头孢他啶-阿维巴坦的耐药性
Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9. doi: 10.1128/AAC.04238-14. Epub 2014 Dec 1.
5
Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.2011 年至 2013 年期间，加利福尼亚州洛杉矶某医疗体系中产碳青霉烯类耐药肠杆菌科细菌的表型和分子特征。
J Clin Microbiol. 2014 Nov;52(11):4003-9. doi: 10.1128/JCM.01397-14. Epub 2014 Sep 10.
6
Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.阿维巴坦与C类β-内酰胺酶：抑制机制、结合口袋的保守性及其对耐药性的影响
Antimicrob Agents Chemother. 2014 Oct;58(10):5704-13. doi: 10.1128/AAC.03057-14. Epub 2014 Jul 14.
7
Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.阿维巴坦对产超广谱C类β-内酰胺酶的阴沟肠杆菌的活性。
J Antimicrob Chemother. 2014 Nov;69(11):2942-6. doi: 10.1093/jac/dku237. Epub 2014 Jun 30.
8
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.美国九个普查地区肠杆菌科中β-内酰胺酶的当代多样性，以及针对产生最常见β-内酰胺酶群的分离株测试头孢他啶-阿维巴坦的活性。
Antimicrob Agents Chemother. 2014;58(2):833-8. doi: 10.1128/AAC.01896-13. Epub 2013 Nov 18.
9
Proliferation and significance of clinically relevant β-lactamases.β-内酰胺酶的临床相关性及其意义。
Ann N Y Acad Sci. 2013 Jan;1277:84-90. doi: 10.1111/nyas.12023.
10
Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).耐头孢洛林/阿维巴坦β-内酰胺酶和孔蛋白突变体的表型特征分析
J Antimicrob Chemother. 2012 Jun;67(6):1354-8. doi: 10.1093/jac/dks079. Epub 2012 Mar 22.
Zotero 插件